Human platelet size, shape, and related functions in health and disease.

Frojmovic, Mony M.; Milton, John

doi:10.1152/physrev.1982.62.1.185

Cited by 241 publications

(134 citation statements)

References 0 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…This technique may be a more sensitive method than platelet aggregation to assess platelet activation. [7][8][9][10][11][12][13][14][15]18,19,21 Thus, others using platelet aggregation did not detect the activating effect of Ang II on human platelets. 5 It is not clear why some subjects reacted more markedly to Ang II than others.…”

Section: Discussionmentioning

confidence: 99%

“…This is important since these agonist are released from activated platelets. 15,[18][19][20][21][22][23][24][25] In this context, it is also relevant that the enhancement of thrombininduced platelet aggregation by Ang II has been reported by others. 6 Losartan, at levels similar to those achieved during treatment, [2][3][4][5] inhibited the stimulatory effect of Ang II on human platelets despite the use of high concentrations 29 of Ang II (in vivo ϭ 10-60 ng/L; in vitro, in our study ϭ 0.25-0.5 g/L).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan

Jagroop

Mikhailidis

2000

J Hum Hypertens

View full text Add to dashboard Cite

Platelet shape change (PSC) is an early phase of platelet activation that precedes platelet aggregation. This phase of platelet activation is essentially aspirin resistant. PSC was monitored, by measuring the median platelet volume (MPV) using a high resolution channelyser. Angiotensin (Ang) II, added in vitro, caused a significant (P ‫؍‬ 0.004) increase in MPV in platelet rich plasma prepared from healthy subjects (n ‫؍‬ 14). This increase in MPV was marked (Ͼ0.40 fl) in 57% (n ‫؍‬ 8) of these subjects and was significantly inhibited (P Ͻ 0.008) by losartan (a selective Ang II antagonist) at con-

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan

Jagroop

Mikhailidis

2000

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…It might have been applied to the mammalian red cell, an oblate spheroid capable of deformation at suffIcient shear stress, or to the unactivated platelet, a relatively rigid oblate spheroid, or its activated form approximating a spiny sphere (22). However, this development had to await new experiments in circular tubes.…”

Section: From Papermaking Fibers To Red Blood Cellsmentioning

confidence: 99%

Stanley Mason: His contribution to the science of Biorheology

Goldsmith

1989

BIR

View full text Add to dashboard Cite

It has been a privilege to assemble and edit this issue of Biorheology dedicated to the memory of a great scientist, Stanley George Mason. In an obituary (1), I have previously given a brief account of his life's work and his studies in physicochemical hydrodynamics. The present article is an account of the manner in which his work has led to the advance of the science of Biorheology, and in particular how it laid the basis of much of our present understanding of the flow properties of mammalian blood cells.

show abstract

“…The effects of an over-activated sympathetic nervous system on the haemostatic system occur in two ways. First, platelet activation via alpha2-adrenoreceptor stimulation which [24] causes shape change and thereby increases MPV [25,26]. Second, larger, activated platelets which are sequestered in the spleen [27] can be released into the circulatory system following the elevated levels of adrenaline [27] that contribute to increased MPV levels; this might be the first mechanism of how RHTN promotes the increased levels of MPV.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Mean Platelet Volume in Patients with Resistant Hypertension, Controlled Hypertension and Normotensives

Surgit¹,

Püşüroğlu²,

Ertürk³

et al. 2015

Eurasian J Med

View full text Add to dashboard Cite

Objective: Patients with resistant hypertension are at increased risk for cardiovascular events. Mean platelet volume (MPV) is an accepted biomarker of platelet activation and considered as a risk factor for cardiovascular disease. The aim of this study was to determine whether MPV levels are higher in resistant hypertensive (RHTN) patients than in controlled hypertensive (CHTN) patients and healthy normotensive controls. Materials and Methods Results:The mean platelet volume levels were significantly higher in RHTN group than in the CHTN and normotensive groups (p<0.001). In correlation analysis office systolic and diastolic blood pressure was positively correlated with MPV. Conclusion:Our study demonstrated that MPV, as an important indicator of platelet activation, was statistically higher in RHTN patients than in CHTN and in normotensive subjects. Elevated MPV levels may help to determine a high risk group for atherosclerosis in RHTN patients. Bulgular: Dirençli hipertansif grupta ortalama trombosit hacmi kontrollü hipertansif ve normotansif gruba göre istatistiksel olarak anlamlı olarak yüksek saptanmıştır (p<0,001). Korelasyon analizinde ofis sistolik ve diastoliktansiyonları ortalama trombosit hacmiyle pozitif korelasyon göstermekteydi. KeywordsSonuç: Çalışmamızda trombosit aktivasyonunun önemli belirteci olan ortalama trombosit hacmi dirençli hipertansif hastalarda diğer gruplara gore anlamlı olarak yüksek saptanmıştır. Artmış ortalama trombosit hacminin dirençli hipertansif hastalarda atheroskleroz açısından yük-sek riskli olanları değerlendirmede kullanılabileceği düşünülmektedir.Anahtar Kelimeler: Dirençli hipertansion, ortalama trombosit hacmi, kontrollü hipertansiyon

show abstract

Human platelet size, shape, and related functions in health and disease.

Cited by 241 publications

References 0 publications

Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan

Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan

Stanley Mason: His contribution to the science of Biorheology

Assessment of Mean Platelet Volume in Patients with Resistant Hypertension, Controlled Hypertension and Normotensives

Contact Info

Product

Resources

About